{
    "id": "676907d3-b374-4baa-8422-c04706409540",
    "indications": {
        "text": "ivabradine tablets hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated : reduce risk hospitalization worsening heart failure adult patients stable , symptomatic chronic heart failure reduced left ventricular ejection fraction . ( 1.1 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "chronic heart failure",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_294422"
            }
        ]
    },
    "contraindications": {
        "text": "adult patients starting dose 2.5 ( vulnerable adults ) 5 mg twice daily food . 2 weeks treatment , adjust dose based heart rate . maximum dose 7.5 mg twice daily . ( 2.1 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "tablets : ivabradine 5 mg tablets formulated orange colored , capsule shaped , film-coated tablets , functionally scored debossing `` `` & `` `` one side `` 2 `` side . supplied follows : \u2022 bottles 60 tablets child-resistant closure ( ndc 72205-336-60 ) \u2022 bottles 180 tablets child-resistant closure ( ndc 72205-336-18 ) ivabradine 7.5 mg tablets formulated orange colored , round shaped , film-coated tablets debossed \u201c myocardial infarction \u201d one side \u201c 1 \u201d side . supplied follows : \u2022 bottles 60 tablets child-resistant closure ( ndc 72205-337-60 ) \u2022 bottles 180 tablets child-resistant closure ( ndc 72205-337-18 ) storage store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "ivabradine contraindicated patients : \u2022 acute decompensated heart failure \u2022 clinically significant hypotension \u2022 sick sinus syndrome , sinoatrial block 3rd degree av block , unless functioning demand pacemaker present \u2022 clinically significant bradycardia [ ( 5.3 ) ] \u2022 severe hepatic impairment [ ( 8.6 ) ] \u2022 pacemaker dependence ( heart rate maintained exclusively pacemaker ) [ ( 7.3 ) ] \u2022 concomitant strong cytochrome p450 3a4 ( cyp3a4 ) inhibitors [ ( 7.1 ) ]",
    "ingredients": [
        {
            "name": "IVABRADINE HYDROCHLORIDE",
            "code": "TP19837BZK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_85969"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "MALTODEXTRIN",
            "code": "7CVR7L4A2D",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25140"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "organization": "Novadoz Pharmaceuticals LLC",
    "name": "Ivabradine",
    "effectiveTime": "20250428",
    "indications_original": "Ivabradine tablets are a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 )",
    "contraindications_original": "Adult patients Starting dose is 2.5\u00a0(vulnerable adults) or 5 mg twice daily with food. After 2 weeks of treatment, adjust dose based on heart rate. The maximum dose is 7.5 mg twice daily. ( 2.1 )",
    "warningsAndPrecautions_original": "Tablets:\n                      Ivabradine 5 mg tablets are formulated as orange colored, capsule shaped, film-coated tablets , functionally scored with debossing \"M\" & \"I\" on one side and \"2\" on other side. They are supplied as follows: \u2022 Bottles of 60 tablets with child-resistant closure (NDC 72205-336-60) \u2022 Bottles of 180 tablets with child-resistant closure\u00a0(NDC 72205-336-18) Ivabradine 7.5 mg tablets are formulated as orange colored, round shaped, film-coated tablets debossed with \u201cMI\u201d on one side and \u201c1\u201d on the other side. They are supplied as follows: \u2022 Bottles of 60 tablets with child-resistant closure\u00a0(NDC 72205-337-60) \u2022 Bottles of 180 tablets with child-resistant closure\u00a0(NDC 72205-337-18)\n                     \n                        Storage\n                     \n                      Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Ivabradine is contraindicated in patients with:  \u2022\u00a0Acute decompensated heart failure  \u2022 Clinically significant hypotension  \u2022\u00a0Sick sinus syndrome, sinoatrial block or 3rd degree AV block, unless a functioning demand pacemaker is present  \u2022 Clinically significant bradycardia\u00a0 [see Warnings and Precautions (5.3)]\n                      \u2022\u00a0Severe hepatic impairment [see Use in Specific Populations (8.6)]\n                      \u2022\u00a0Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions (7.3)] \n                      \u2022\u00a0Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions (7.1)]",
    "drug": [
        {
            "name": "Ivabradine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_85966"
        }
    ]
}